STOCK TITAN
  1. Home
  2. Sec-filings
  3. RDY
  4. [6-K] DR REDDYS LABORATORIES LTD Current Report (Foreign Issuer)

Dr. Reddy’s issues 4,110 shares to employees

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
6-K

Rhea-AI Filing Summary

DR. REDDY’S LABORATORIES LIMITED (symbol RDY) reports the allotment of 4,110 equity shares of face value Re.1 each on August 26, 2026 to eligible employees following exercise of stock options under the Dr. Reddy’s Employees Stock Option Scheme, 2002. These fully paid shares are equity shares that rank pari passu with existing shares. After this issuance, total issued shares are 83,46,80,910 and total issued share capital is Rs. 83,46,80,910, while total paid-up capital is 83,46,79,910 equity shares of Re.1 each, aggregating to Rs. 83,46,79,910, reflecting 1,000 forfeited shares from September 1988.

Positive

  • None.

Negative

  • None.

Filing Explained

The disclosed consideration was Re.1 per share with no premium: the 4,110 shares issued on August 26, 2026 were allotted at the stated exercise price, without an additional per-share premium.

Number of shares issued 4,110 equity shares Allotted on August 26, 2026 on exercise of employee stock options
Exercise price per share Re.1/- per share Price paid by employees under Dr. Reddy’s Employees Stock Option Scheme, 2002
Par value of shares Re. 1/- Face value of each equity share
Total issued shares after issue 83,46,80,910 shares Total issued equity shares after August 26, 2026 allotment
Total issued share capital after issue Rs. 83,46,80,910/- Issued equity share capital following the ESOP allotment
Total paid up capital after issue Rs. 83,46,79,910/- 83,46,79,910 equity shares of Re.1 each after this issue
Distinctive numbers of new shares 834675801 to 834679910 Range for the 4,110 newly allotted equity shares
pari passu financial
"Yes, the shares rank pari passu with the existing shares"
An instruction that different claims, securities, or creditors are treated equally and share rights or payments on the same priority level. For investors, it means their position will be paid or have voting power alongside others in the same class rather than being favored or subordinated—think of several people standing in one bus line who all get on together rather than some cutting ahead. That parity affects expected recovery in reorganizations, dividend order, and relative risk.
SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021 regulatory
"Details under Regulation 10(c) of the SEBI (Share Based Employee Benefits and Sweat Equity)"
Dr. Reddy’s Employees Stock Option Scheme, 2002 financial
"pursuant to exercise of their Stock Options under Dr. Reddy’s Employees Stock Options Scheme, 2002"
ISIN financial
"ISIN Number of the shares if issued in Demat: INE089A01031"
A 12-character International Securities Identification Number (ISIN) is a unique code that acts like a passport for a specific stock, bond or other tradable security so it can be identified worldwide. Investors and systems use it to ensure they are buying, selling and tracking the exact same instrument across exchanges and data feeds, which prevents costly mix-ups and makes portfolio reporting, settlement and regulatory checks simpler and more reliable.
Employee Stock Option Scheme financial
"under the erstwhile the SEBI (Employee Stock Option Scheme and Employee Stock Purchase"

FAQ

What share issuance did DRREDDY (RDY) announce on August 26, 2026?
The company allotted 4,110 equity shares of Re.1 each on August 26, 2026 to eligible employees upon exercise of stock options under the Dr. Reddy’s Employees Stock Option Scheme, 2002.

What is Dr. Reddy’s (RDY) total issued share capital after this ESOP allotment?
After the allotment, total issued shares are 83,46,80,910 and total issued share capital is Rs. 83,46,80,910.

What is Dr. Reddy’s (RDY) total paid-up share capital after this issue?
Total paid-up capital is 83,46,79,910 equity shares of Re.1 each, aggregating to Rs. 83,46,79,910, reflecting a 1,000 share difference due to forfeited shares from September 1988.

At what price were the new DRREDDY (RDY) ESOP shares issued?
The exercise price per share for the stock options was Re.1 per share, equal to the par value, with no premium charged.

On which exchanges are Dr. Reddy’s (RDY) shares and ADRs listed?
Equity shares are listed on BSE Limited and National Stock Exchange of India Limited. ADRs are listed on New York Stock Exchange Inc. and NSE IFSC Limited.

What is the ISIN of Dr. Reddy’s (RDY) equity shares involved in this allotment?
The ISIN for the equity shares is INE089A01031. The distinctive numbers for the newly allotted shares range from 834675801 to 834679910.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google


 


SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

Form 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

 

August, 2026

 

Commission File Number 1-15182 

 

DR. REDDY’S LABORATORIES LIMITED

(Translation of registrant’s name into English)

 

8-2-337, Road No. 3, Banjara Hills

Hyderabad, Telangana 500 034, India

+91-40-49002900

(Address of principal executive office)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

Form 20-F x                          Form 40-F ¨

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):  ______

 

Note:  Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):  ______

 

Note:  Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant’s “home country”), or under the rules of the home country exchange on which the registrant’s securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant’s security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.

 

Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

 

Yes ¨                          No x

 

If “Yes” is marked, indicate below the file number assigned to registrant in connection with Rule 12g3-2(b): 82-________.


 



EXHIBITS

 

Exhibit

Number

 

Description of Exhibits

 

 

 

99.1


Intimation dated August 26, 2026

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

 

DR. REDDY’S LABORATORIES LIMITED

(Registrant)

 

 

Date: August 26, 2026

By:

/s/ K Randhir Singh

 

 

Name:

K Randhir Singh

 

 

Title:

Company Secretary

 


Exhibit 99.1

 

Dr. Reddy's Laboratories Ltd.

8-2-337, Road No. 3, Banjara Hills

Hyderabad – 500 034, Telangana, India

 

CIN: L85195TG1984PLC004507

 

Tel:      + 91 40 4900 2900

Fax:     + 91 40 4900 2999

Email: mail@drreddys.com

Web:   www.drreddys.com

 

August 26, 2026

 

National Stock Exchange of India Ltd. (Scrip Code: DRREDDY)

BSE Ltd. (Scrip Code: 500124)

New York Stock Exchange Inc. (Stock Code: RDY)

NSE IFSC Ltd. (Stock Code: DRREDDY)

 

Dear Sir/Madam,

 

Ref:

Disclosure under Regulation 30 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015

 

Sub:

Allotment of Equity Shares on exercise of Stock Options under ESOPs

 

This is to inform you that the Company has allotted 4,110 equity shares of Re.1/- each of the Company, fully paid up, on August 26, 2026, to eligible employees pursuant to exercise of their Stock Options under Dr. Reddy’s Employees Stock Options Scheme, 2002.

 

Further, please find enclosed the details as required under Regulation 10(c) of the SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021.

 

Thanking you.

 

Yours faithfully,

For Dr. Reddy’s Laboratories Limited


K Randhir Singh

Company Secretary, Compliance Officer & Head-CSR

 

Encl: as above

 

 


Dr. Reddy's Laboratories Ltd.

8-2-337, Road No. 3, Banjara Hills

Hyderabad – 500 034, Telangana, India

 

CIN: L85195TG1984PLC004507

 

Tel:      + 91 40 4900 2900

Fax:     + 91 40 4900 2999

Email: mail@drreddys.com

Web:   www.drreddys.com

 

Details under Regulation 10(c) of the SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021

1

Company name and address of Registered Office:

Dr. Reddy's Laboratories Limited

8-2-337, Road No.3, Banjara Hills, Hyderabad – 500034

2

Name of the Stock Exchanges on which the company’s shares are listed:

BSE Limited

National Stock Exchange of India Limited

New York Stock Exchange Inc. (ADRs)

NSE IFSC Limited (ADRs)

3

Filing date of the statement referred in Regulation 10(b) of the SEBI (Share Based Employee Benefits) Regulations, 2021 with Stock Exchange:

The Schemes were institutionalised under the erstwhile the SEBI (Employee Stock Option Scheme and Employee Stock Purchase Scheme) Guidelines, 1999 and appropriate details under Schedule V were filed. The Schemes comply with provisions of the SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021.

4

Filing Number, if any: NA

5

Title of the Scheme pursuant to which shares are issued, if any:

Dr. Reddy’s Employees Stock Option Scheme, 2002

6

Kind of security to be listed: Equity Shares

7

Par value of the shares: Re. 1/-

8

Date of issue of shares: August 26, 2026 (Date of allotment on exercise)

9

Number of shares issued: 4,110 equity shares

10

Share Certificate No., if applicable: NA

11

Distinctive number of the share, if applicable: 834675801 to 834679910

12

ISIN Number of the shares if issued in Demat: INE089A01031

13

Exercise price per share: Re.1/- per share

14

Premium per share: Nil

 15

Total Issued shares after this issue: 83,46,80,910 (*)

16

Total Issued share capital after this issue: Rs. 83,46,80,910 /-

17

Details of any lock-in on the shares: NA

18

Date of expiry of lock-in:  NA

19

Whether shares identical in all respects to existing shares if not, when will they become identical?
Yes, the shares rank pari passu with the existing shares

20

Details of listing fees, if payable: NA

(*) Total paid up capital after this issue: 83,46,79,910 equity shares of Re.1 each, aggregating to Rs. 83,46,79,910/- (difference of 1,000 due to forfeited shares of Re. 1/- each in September 1988 on account of non-payment of allotment money.)

 



Source: View Original Filing on SEC EDGAR

Filing Exhibits & Attachments

1 document

Press Releases